Life Science Nation Newsletter  | February 8,  2018  |  Issue 252


  The LSN Story   |   Investor Platform   |   Company Platform   |   RESI Conference   |   Fundraising Consulting
Life Science Investor Mandates (Feb. 1 - Feb. 7 )
Seeking Global Opportunities with Focus in Therapeutics and Digital Health in Life Sciences
Focused on Diagnostics Investments
Invests in Early-Stage Therapeutics, Molecular Diagnostics, and Digital Health
Looks to Invest in Mobility and Data-Driven Technologies in Life Sciences and Healthcare
In This Issue
News
Nature BioEntrepreneur Features LSN: Aligning Needs
LSN Services
Click to see investors that are a fit for your product and stage of development

Click here if you are a service provider and want to see a list of funded life science companies that are a fit for you

Click here if you want to receive free, targeted early stage dealflow for your life science investment firm

Free Copy of LSN's Book

LSN Videos
By Cole Bunn, Senior Research Analyst, LSN

The world of early stage biotech/medtech investment is far less than straightforward, and entrepreneurs who have been through the arduous, frustrating process of raising money will second that. Adding to this challenge, other than a personal network, fundraising CEOs have limited resources for learning which investors are in their universe and how to get in touch with them - LSN was founded to address this exact problem.

When raising a seed or series A financing, most people's mind goes straight to a few brand name VCs and angel groups in their backyard, and mistakenly think this is going to get the job done. The reality is that fundraising is a numbers game, and there are thousands of groups across the world that are not well known and don't necessarily fall into one of these investor buckets, but may be a great fit for your venture. The problem is that you have no efficient way of identifying who these groups are, if they are a fit and most importantly, a way to reach them...

By Lucy Parkinson, Director of Research, LSN

LSN created the LSN Investor Platform, which is the only early stage life science investor platform that goes across the silos of drugs, devices, diagnostics and healthcare IT. Over 600 clients have used this service, raising millions of dollars from investors located all around the globe. We've recently updated our video to reflect the latest generation of the cloud-based investor and strategic partnering database - take a look below!


By Christine A. Wu, Senior Research Analyst, LSN

We see a lot of innovative point-of-care diagnostics out there, but what do these opportunities truly mean to diagnostic investors? How do diagnostic companies climb the reimbursement hurdle and how will the actionable information provided by these new diagnostics change healthcare delivery? Diagnostic investors discussed these questions at LSN's Redefining Early Stage Investments Conference in San Francisco on January 9 th

Moderated by Akhil Saklecha, Partner of Artiman Ventures, we heard from:
  • Jenny Rooke, Venture Partner, F-Prime Capital
  • Alessio Beverina, Founder & Managing Partner, Panak├Ęs Partners
  • Eric Hargarten, Investment Associate, Sandbox Industries
  • Wouter Meuleman, Director of Investments, Illumina Ventures

Created & Produced by